Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ramea ODF is an orally dispersible film (ODF) formulation of ramosetron, a selective serotonin 5-HT3 receptor antagonist, developed by Kwang Dong Pharmaceutical. It is primarily indicated for the prevention and treatment of nausea and vomiting, particularly chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). The ODF technology allows the medication to dissolve rapidly on the tongue without the need for water, which is highly beneficial for patients experiencing severe emesis or those with difficulty swallowing. By selectively blocking 5-HT3 receptors in both the peripheral gastrointestinal tract and the central nervous system's chemoreceptor trigger zone, ramosetron effectively inhibits the emetic reflex triggered by serotonin release.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ramea ODF.